Critical Survey: Guardian Pharmacy Services (NYSE:GRDN) & Metagenomi (NASDAQ:MGX)

Metagenomi (NASDAQ:MGX) and Guardian Pharmacy Services (NYSE:GRDN) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Profitability

This table compares Metagenomi and Guardian Pharmacy Services’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Metagenomi	-172.21%	-31.21%	-22.21%
Guardian Pharmacy Services	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of current ratings and target prices for Metagenomi and Guardian Pharmacy Services, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	0	0	4	0	3.00
Guardian Pharmacy Services	0	0	3	0	3.00

Metagenomi currently has a consensus price target of $13.00, suggesting a potential upside of 790.41%. Guardian Pharmacy Services has a consensus price target of $25.67, suggesting a potential upside of 19.96%. Given Metagenomi’s higher possible upside, equities research analysts clearly believe Metagenomi is more favorable than Guardian Pharmacy Services.

Earnings and Valuation

This table compares Metagenomi and Guardian Pharmacy Services”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metagenomi	$52.29 million	1.04	-$78.06 million	($2.11)	-0.69
Guardian Pharmacy Services	$1.23 billion	1.10	-$87.29 million	N/A	N/A

Metagenomi has higher earnings, but lower revenue than Guardian Pharmacy Services.

Summary

Guardian Pharmacy Services beats Metagenomi on 5 of the 8 factors compared between the two stocks.

About Metagenomi

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

About Guardian Pharmacy Services

Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs. The company was founded in 2003 and is based in Atlanta, Georgia.